ClinicalTrials.gg
RecruitingNCT05975580PROJECT-BARIUpdated Oct 19, 2026

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

A Phase 4 interventional study of Topiramate and Phentermine in Obesity, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of California, Irvine · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Updated Oct 19, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing topiramate in Obesity — 3 open to participants now, 4 under way, none of them phase 3. Topiramate · Obesity.

Planned enrollment
17th of 33
120 · median 120
Started
2023
the only one that year
Phase 4
7 of 33
2 open now
Registered
31st of 33
by date
Lead sponsor
1 of 33
University of California, Irvine

Among the 33 studies testing topiramate in Obesity, this one is the 17th largest by planned enrollment, is the only one that started in 2023, is one of 7 in phase 4, and was the 31st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 33 studies testing topiramate in Obesity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About topiramate

Topiramate: first FDA approval 1996 (TOPAMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing topiramate in Obesity, or all of them as a file.
02

Study summary

This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.

Read the detailed description

Although bariatric surgery is the most effective treatment for severe obesity, a large proportion of patients experience significant weight regain with longer follow-up.

In this randomized controlled trial employing a SMART design, a total of 120 subjects with weight regain after bariatric surgery, will be initially randomized in a 3:3:2 ratio to daily treatment with topiramate (TPM) or phentermine (PHEN) or placebo. After 4 months, responders (those with ≥5% weight loss) will continue the same treatment, while nonresponders will be re-randomized to a higher dose of the same drug or phentermine/topiramate combination (PHEN/TPM) during Months 5-12. All subjects will receive diet and lifestyle counseling throughout the study.

Aim 1: To determine whether pharmacotherapy can reverse post-bariatric surgery weight regain.

Hypothesis: Compared to placebo, all three active drug therapies - TPM, PHEN, and PHEN/TPM will lead to greater percent weight loss at Month 12.

Aim 2: To examine change in energy intake assessed by a dietitian interview.

Hypothesis: Compared to placebo, active drug therapies will lead to greater reduction in energy intake at Month 12.

Aim 3: To examine changes in the most common maladaptive eating behaviors in the post-bariatric surgery patients - grazing, loss-of-control eating, and binge eating.

Hypothesis: Compared to placebo, active drug therapies will lead to decreased maladaptive eating behaviors.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Bariatric surgery
  • Weight regain
  • Antiobesity drugs
  • Treatment of weight regain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged 18-70 years
  2. Had sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) at least 18 months ago
  3. Weight regain of ≥5% relative to post-surgery nadir weight
  4. (BMI) ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidities
  5. Women of must be using appropriate to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry
  6. Must be able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes
  2. Insulin-dependent type 2 diabetes
  3. Fasting plasma glucose (FPG) ≥240 mg/dL
  4. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥100 mm Hg on the average of three seated measurements after being at rest for at least 5 minutes
  5. History of significant (as determined by the investigator) and unstable cardiovascular disease including coronary artery disease, arrhythmias, severe congestive heart failure, or stroke
  6. Use of monoamine oxidase inhibitors, current or within 2 weeks
  7. Hyperthyroidism or other significant thyroid disease
  8. Angle-closure glaucoma
  9. Agitated states
  10. History of drug abuse within the past year
  11. Known or idiosyncrasy to sympathomimetic amines
  12. Severe hepatic disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis without portal hypertension or cirrhosis is acceptable)
  13. End-stage renal disease
  14. History of nephrolithiasis
  15. Serum triglycerides ≥500 mg/dL
  16. Cancer, not in remission, within the past 2 years except for adequately treated basal cell, squamous cell skin cancer, or in-situ cervical cancer
  17. History of psychosis or bipolar disorder
  18. Suicidal ideation or unstable/untreated major depressive disorder within the past year
  19. Use of antidepressant medication that has not been at stable dose for at least 3 months
  20. Hospital Anxiety and Depression Scale (HADS) score of ≥11 for depression or anxiety items
  21. Binge Eating Scale (BES) score of ≥27
  22. Alcohol use disorder within the past year
  23. Epilepsy
  24. Currently taking phentermine or topiramate or the combination, or products containing these drugs
  25. Currently taking stimulants (e.g., Attention Deficit Hyperactivity Disorder medications)
  26. Current use of prescription or over-the-counter weight loss drugs or supplements
  27. Taking prescription or over-the-counter drugs or products, which in the opinion of the PI, could be associated with significant effects on body weight
  28. Planning additional bariatric surgery procedures in the next 13 months
  29. History of revisional bariatric surgery (revisional surgery after adjustable gastric banding is acceptable)
  30. Currently participating in another weight loss program or have plans to participate in the next 13 months
  31. Smoking cessation within the previous 3 months or plans to quit smoking in the next 13 months
  32. Pregnant or breastfeeding or planning pregnancy in the coming 13 months
  33. History of, or any existing condition that, in the opinion of the Principal Investigator, would interfere with the study outcomes or place the subject at unacceptable risk by participating in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A: Topiramate 50 mg

    Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.

    Drug: Topiramate

  • Experimental
    Group B: Topiramate 100 mg

    Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 15/100 mg during Months 5-12. Doses will be titrated in Month 5.

    Drug: Topiramate

  • Experimental
    Group C: Phentermine 15 mg/Topiramate 100 mg

    Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 15/100 mg during Months 5-12. Doses will be titrated in Month 5.

    Drug: Topiramate · Drug: Phentermine

  • Experimental
    Group D: Phentermine 15 mg

    Phentermine will be started at 7.5 mg daily and the dose will be increased to 15 mg after 15 days. Responders at Month 4 will continue the same treatment until Month 12.

    Drug: Phentermine

  • Experimental
    Group E: Phentermine 30 mg

    Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 30 mg or phentermine/topiramate 15/100 mg during Months 5-12. Doses will be titrated in Month 5.

    Drug: Phentermine

  • Experimental
    Group F: Phentermine 15 mg/Topiramate 100 mg

    Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 30 mg or phentermine/topiramate 15/100 mg during Months 5-12. Doses will be titrated in Month 5.

    Drug: Topiramate · Drug: Phentermine

  • Placebo comparator
    Group P: Placebo

    Placebo group will receive placebo.

    Drug: Placebo

Interventions

  • Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

  • Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine

  • DrugPlacebo

    Placebo is an inactive substance.

06

What researchers measure

Primary outcomes

  1. Percent weight loss at Month 12 - Topiramate vs placebo

    Topiramate (Group 1 \[Group A + Group B\]) vs placebo (Group P)

    Time frame: Month 0, Month 12

  2. Percent weight loss at Month 12 - Phentermine vs placebo

    Phentermine (Group 2 \[Group D + Group E) vs placebo (Group P)

    Time frame: Month 0, Month 12

  3. Percent weight loss at Month 12 - Phentermine/Topiramate

    Phentermine/Topiramate (Group 3 \[Group C + Group F\]) vs placebo (Group P)

    Time frame: Month 0, Month 12

Secondary outcomes

  1. Energy intake

    Change in energy intake in kcal/d assessed with a dietitian interview. Comparisons between Groups 1, 2, 3 vs placebo.

    Time frame: Month 0, Month 12

Other outcomes

  1. Grazing

    Change in grazing behavior, assessed with the Grazing Questionnaire. Comparisons between Groups 1, 2, 3 vs placebo.

    Time frame: Months 0, 4, 12

  2. Loss-of-control eating

    Change in loss-of-control eating, assessed with the Loss-of-Control Eating Scale. Comparisons between Groups 1, 2, 3 vs placebo.

    Time frame: Months 0, 4, 12

  3. Binge eating

    Change in binge eating, assessed with the Binge Eating Scale. Comparisons between Groups 1, 2, 3 vs placebo.

    Time frame: Months 0, 4, 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Noria SF, Shelby RD, Atkins KD, Nguyen NT, Gadde KM. Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment. Curr Diab Rep. 2023 Mar;23(3):31-42. doi: 10.1007/s11892-023-01498-z. Epub 2023 Feb 8. PubMed 36752995 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jul 2027, 47 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 47 months is above that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 4, 2023
StartActual
Aug 29, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: p•••@hs.uci.edu · •••6155→r•••@hs.uci.edu · •••5067; q•••@hs.uci.edu→m•••@hs.uci.edu. See the current contact
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of California Irvine Medical Center · Orange, United StatesContact p•••@hs.uci.edu · •••6155→r•••@hs.uci.eduContact q•••@hs.uci.edu→m•••@hs.uci.edu
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Contact Study contact changed: p•••@hs.uci.edu · •••6155→r•••@hs.uci.edu · •••5067; q•••@hs.uci.edu→m•••@hs.uci.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of California Irvine Medical Center · Orange, United StatesContact p•••@hs.uci.edu · •••6155→r•••@hs.uci.eduContact q•••@hs.uci.edu→m•••@hs.uci.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05975580
Responsible party
Kishore M Gadde, MD (Professor In Residence, Surgery, University of California, Irvine) — Principal investigator
First posted
Aug 4, 2023
Start date
Aug 29, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Raha Esmaeili
Contact
rahae@hs.uci.edu
7144895067
Melanie Morales Vargas
Contact
msmoral2@hs.uci.edu
Kishore M Gadde, MD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Topiramate · Phentermine

Start the discussion